DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression
The gene Tfcp2l1 has emerged as a central player linking key processes in cancer biology: hypoxia, immortalization, dedifferentiation, and tumor progression. Originally identified for its role in maintaining pluripotency in embryonic stem cells, Tfcp2l1 has been found to reappear in various cancers, especially under conditions of low oxygen (hypoxia). Hypoxia, a common feature of solid tumors, triggers the reactivation of developmental genes like Tfcp2l1, enabling cancer cells to dedifferentiate and adopt stem cell-like properties. This dedifferentiation facilitates the immortalization of cells—allowing them to bypass senescence and continue proliferating. Tfcp2l1 contributes to this process by regulating transcriptional networks that suppress differentiation and support self-renewal. Its expression correlates with poor prognosis in several cancers, highlighting its potential role in tumor aggressiveness and resistance to therapy. By acting at the intersection of cellular plasticity, stress adaptation, and oncogenic transformation, Tfcp2l1 may serve as a molecular bridge linking early developmental programs with malignant behaviors. Understanding how Tfcp2l1 integrates signals from hypoxic stress and drives dedifferentiation could uncover new therapeutic targets aimed at reversing or halting tumor progression., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I, Agencia Estatal deInvestigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER,UE): PID2021-122629OB-I00, PID2024-155394OB-I00 and RED2024-153635-T (iDIFFER network) grants from AEI-MICIU/ 10.13039/501100011033 and, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR” from CIBER de Cáncer(CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-122629OB-I00
,
AEI PID2024-155394OB-I00
DOI: http://hdl.handle.net/10261/402565, https://api.elsevier.com/content/abstract/scopus_id/105013199907
HANDLE: http://hdl.handle.net/10261/402565, https://api.elsevier.com/content/abstract/scopus_id/105013199907